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Positron Emission Tomography Imaging Predicts Adverse
Outcomes in Patients Assessed for Myocardial Ischemia
Maria C. Ziadi, MD,* Robert A. deKemp, PHD,* Kathryn A. Williams, MS,† Ann Guo, MENG,*
Benjamin J. W. Chow, MD,* Jennifer M. Renaud, MSC,* Terrence D. Ruddy, MD,*
Niroshi Sarveswaran, BHSC,* Rebecca E. Tee, MSC,* Rob S. B. Beanlands, MD*
Ottawa, Ontario, Canada
Objectives We evaluated the prognostic value of myocardial flow reserve (MFR) using rubidium-82 (82Rb) positron emission
tomography (PET) in patients assessed for ischemia.
Background The clinical value of MFR quantification using 82Rb PET beyond relative myocardial perfusion imaging remains
uncertain.
Methods We prospectively enrolled 704 consecutive patients; 677 (96%) completed follow-up (median 387 days
[interquartile range: 375 to 416 days]). Patients were divided into 4 groups: I, normal summed stress score
(SSS) (4) and normal myocardial flow reserve (MFR) (2); II, normal SSS and MFR 2; III, SSS 4 and
MFR 2; IV, SSS 4 and MFR 2.
Results For patients with a normal SSS and those with an abnormal SSS, there were significant differences in outcomes
for hard events (cardiac death and myocardial infarction) between patients with MFR 2 and those with
MFR 2 (I: 1.3% vs. II: 2% [p  0.029]; III: 1.1% vs. IV: 11.4% [p  0.05]) and for major adverse cardiac events
(MACE) (p  0.003 and p  0.001, respectively). In the adjusted Cox model, MFR was an independent predictor
of hard events (hazard ratio: 3.3; 95% confidence interval: 1.1 to 9.5; p  0.029) and MACE (hazard ratio: 2.4,
95% confidence interval: 1.4 to 4.4, p  0.003). The incremental prognostic value of the MFR over the SSS was
demonstrated by comparing the adjusted SSS model with and without the MFR for hard events (p  0.0197)
and MACE (p  0.002).
Conclusions MFR quantified using 82Rb PET predicts hard cardiac events and MACE independent of the SSS and other pa-
rameters. Routine assessment of 82Rb PET–quantified MFR could improve risk stratification for patients being
investigated for ischemia. (J Am Coll Cardiol 2011;58:740–8) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.065cThe diagnostic and prognostic value of relative myocardial
perfusion imaging (MPI) using single-photon emission to-
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accepted January 31, 2011.mography (1,2) and positron emission tomography (PET)
(3–6) is well established. Relative MPI has limitations because
it often uncovers only the territory supplied by the most severe
coronary stenosis. This could underestimate the extent of
coronary artery disease (CAD) (6–8). Also, relative MPI
annot define the presence of subclinical atherosclerosis.
See page 749
In addition to relative MPI, PET imaging enables non-
invasive quantification of myocardial perfusion. Various
clinical applications for myocardial flow reserve (MFR)
(stress myocardial blood flow [MBF]/rest MBF) have been
proposed (8–15). To date, however, MFR measurement has
not been integrated into clinical practice because studies
demonstrating added clinical value have been limited.
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August 9, 2011:740–8 Myocardial Flow Reserve by PET and Outcomes in IschemiaAmong available validated PET tracers for flow quanti-
fication, rubidium-82 (82Rb) has the most potential for
road clinical application. It is more widely available in
orth America than other cyclotron-based PET tracers.
till, there are no large studies that evaluated the prognostic
alue of flow quantification using 82Rb PET. If the added
rognostic value of MFR quantification with 82Rb were
demonstrated, this could have an important impact given
the growing use of 82Rb PET worldwide.
We sought to assess the prognostic value of 82Rb PET–
uantitated MFR in patients being investigated for isch-
mia. We hypothesized that patients with reduced MFR
ould have higher cardiac event rates than those with
reserved MFR and 82Rb MFR would be an independent
redictor of adverse outcomes.
ethods
atient population. We prospectively enrolled patients
ith known or suspected CAD, referred for dipyridamole
82Rb PET MPI for evaluation of ischemia at the University
of Ottawa Heart Institute, Ottawa, Ontario, Canada. All
patients provided written informed consent for inclusion in
the study.
Patients were excluded if they did not have MBF data
available because dynamic acquisition was not acquired or
because of other technical factors (16). Patients who under-
went dobutamine, exercise, and/or 13N-ammonia (13NH3)
ET were also excluded. For those with more than 1 82Rb
ET scan, only the first scan was used.
ET imaging. Patients refrained from caffeine 12 h and
theophyllines for 48 h before the MPI study (17,18).
Antianginal medications were withheld the morning of the
test. After an overnight fast, patients were positioned in a
3-dimensional PET system (Discovery Rx/VCT, GE
Healthcare, Milwaukee, Wisconsin) (19). A low-dose
(0.5 mSv), fast helical (1.5 s) computed tomography scan
(120 kpv with axial and angular milliampere modulation at
a noise index of 50) was acquired for attenuation correction.
Then, 10 MBq/kg of 82Rb was administered intravenously
using a custom elution system to ensure dead-time losses
remained 50% (20,21). A 17-frame, 10-min dynamic
82Rb scan was acquired with a parallel list-mode acquisition.
Pharmacological stress and imaging. After rest PET MPI,
a dipyridamole stress test was performed (0.14 mg/kg/min over
5 min). Then 10 MBq/kg of 82Rb was infused 3 min after
completion of the vasodilator infusion. Stress images were
acquired per rest MPI. A repeat low-dose computed tomog-
raphy scan was acquired after stress images for attenuation
correction.
Image processing. Images were reconstructed using Fou-
rier rebinning and filtered back-projection with a 12-mm
3-dimensional Hann window of the ramp filter. Automatic
reorientation of the images, automatic extraction of mean
myocardial and cavity time-activity curves (21,22), and
generation of polar maps of absolute MBF and MFR were cperformed using our FlowQuant
software (Ottawa Heart Institute
Research Corporation, Ottawa,
Ontario, Canada) (16).
Electrocardiographic gating. The
list-mode data from 2.5 to 10
min were replayed to reconstruct
electrocardiographic-gated im-
ages. Left ventricular ejection
fractions (LVEFs) were deter-
mined using 4DM software (IN-
VIA, Ann Arbor, Michigan).
82RbPETanalysis. STATIC IMAGE
NTERPRETATION. Images were
interpreted using a 17-segment
model (23) and a 5-point scoring
system blinded to clinical, imag-
ing, and flow data by an experi-
enced blinded observer and then
independently compared with
the clinical imaging report. Any
discrepancies were then reviewed independently by an
additional experienced blinded observer. Any remaining
discrepancies were settled by consensus. Summed stress
score (SSS), summed rest score, and summed difference
score (summed difference score  SSS  summed rest
score) were calculated. An SSS 4 was considered abnor-
mal (2,14). The LVEF during rest and stress and LVEF
reserve (stress-rest LVEF) (6) were determined. The pres-
ence or absence of transient ischemic dilation was noted.
82RB FLOW QUANTIFICATION. MBF was quantified using a
1-tissue compartment model with a flow-dependent extrac-
tion correction (0). The washout rate was expressed as k2 
K1/DV; DV, the distribution volume of
82Rb in tissue, was
et to a constant value (25) for each scan by fitting the model
o the region of normal relative uptake (75% to 100% of
aximum). MFR 2.0 was considered abnormal (9,14).
ELECTROCARDIOGRAPHIC ANALYSIS. Stress electrocardio-
rams were reviewed and interpreted by blinded observers
sing recommended practice guidelines (26).
ardiac event definitions and follow-up. The primary
utcome was the prevalence of hard cardiac events: myocar-
ial infarction (MI) and cardiac death. A secondary out-
ome was the prevalence of major adverse cardiac events
MACE): cardiac death, MI, late revascularization (percu-
aneous coronary intervention or coronary artery bypass
raft) and cardiac hospitalization (e.g., acute coronary syn-
rome and heart failure). Coronary artery bypass graft or
ercutaneous coronary intervention within 90 days after the
ET scan was considered to be triggered by the relative
PI results and therefore censored from analysis (4).
efinitions of each variable were described previously (4,27).
Elective admissions for procedures (e.g., implantable
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
LVEF  left ventricular
ejection fraction
MACE  major adverse
cardiac event(s)
MFR  myocardial flow
reserve
MI  myocardial infarction
MPI  myocardial perfusion
imaging
13NH3 
13N ammonia
PET  positron emission
tomography
82Rb  rubidium-82
SSS  summed stress
scoreardioverter-defibrillator) were not counted as events. For
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or analysis.
Follow-up information was acquired for 677 of 704
atients (96%), the majority via telephone interview (suc-
essful in 609 of 677 patients; 90%). Events are based on the
est available data as of March 2010. When telephone
ontact was unsuccessful, a record search (n  12; 2%) was
used. Telephone contact with a close family member of the
patient was obtained for some patients (n  56; 8%).
Additional data were gathered from medical charts and/or
referring physicians. Verification of events was obtained
from patient charts, hospital records, death certificates,
and/or contact with referring physicians.
Statistical analysis. Multivariable Cox proportional haz-
ards models were used to assess the independent prognostic
value of the MFR. Individual predictor’s Wald chi-square
statistics are provided as an indicator of the relative impor-
tance of the predictor. For the MFR and SSS, accepted
cutoff values were used to create the variables of primary
interest. Adjusted Kaplan-Meier curves illustrate the incre-
mental value of the MFR over the SSS. Cox model
contrasts were used to test for all MFR and SSS group
differences. Interactions between the MFR and SSS were
tested in the models and were not statistically significant.
Therefore, the SSS and MFR could be assessed as indepen-
dent predictors without the interaction.
To prevent overfitting of the multivariable Cox propor-
tional hazards models, only baseline characteristics included
in Tables 2 and 3 with p values 0.05 with MFR and SSS
were considered in the full models. For the hard events
model, only 3 significant baseline characteristics (previous
MI, stress LVEF, and peripheral vascular disease) were
considered in the model with the MFR and SSS. Stepwise
selection was used to create the adjusted model controlling
for confounding. PVD was not significant in the final hard
events model.
To show the incremental value of the MFR, the adjusted
model with the SSS MFR was compared with the model
with the SSS alone using a likelihood ratio chi-square test.
We demonstrated the added value of the MFR as both a
continuous variable and a binary variable. We used the
dichotomous variable because it represents a more straight-
forward way to display in survival curves and odds ratios.
The net reclassification improvement and the integrated dis-
crimination improvement were calculated as additional tools.
Patient subgroups. Four groups were generated: I, normal
SSS 4 and normal MFR 2; II, normal SSS 4 and
abnormal MFR 2; III, abnormal SSS 4 and normal
MFR 2; and IV, abnormal SSS 4 and normal MFR2.
Hard cardiac events and MACE across different subgroups
were evaluated.
Results
Baseline patient characteristics. Among 957 scans per-
formed, 243 were excluded: 48 with dobutamine or exercise
Pstress; 144 13NH3 scans; 20 repeat scans; 40 inadequate or
ncomplete dynamic data to enable quantification; and 1
atient with previously known dilated cardiomyopathy.
hus, 704 consecutive patients were enrolled: 677 (96%)
ad successful follow-up, with 58 patients censored due to
arly revascularization. Median follow-up was 387 days
interquartile range: 375 to 416 days).
The demographic and 82Rb PET imaging characteristics
of patients with follow-up are given in Table 1. The
characteristics of the patients who were lost to follow-up
(n  27) were similar.
Outcome data. During follow-up, among the 677 patients
in this study, there were 27 hard events (4%), 12 cardiac
deaths (1.8%), and 16 nonfatal MIs (2.4%) (1 patient had
MI and then cardiac death). For MACE, there were 71 first
events (71 of 677; 10.5%). Among patients with events, 20
patients (20 of 71; 28%) underwent late revascularization as
first events (13 percutaneous coronary interventions, 7 cor-
onary artery bypass grafts), and 29 patients were admitted:
Demographics and PET Parametersfor Patients With Follow-UpTable 1 Demographics nd PET Parametersfor Patients With Follow-Up
Variable
No Follow-Up
(n  27)
Follow-Up
(n  677) p Value
Age, yrs 57 15 64 12 0.006
Male 14 (52) 416 (61) 0.322
Hypertension 18 (67) 461 (68) 0.837
Diabetes 8 (30) 195 (29) 1.000
Smoking 19 (70) 431 (64) 0.545
Family history of CAD 14 (52) 336 (50) 0.847
Hyperlipidemia 20 (74) 467 (69) 0.674
PVD 4 (15) 126 (19) 0.802
Known CAD 14 (52) 390 (58) 0.558
Previous MI 9 (33) 268 (40) 0.554
Previous revascularization 12 (44) 304 (45) 1.000
CCS angina class II 10 (37) 274 (40) 0.842
NYHA functional class II 8 (30) 208 (31) 1.000
82Rb PET standard imaging
parameters
SSS 4.9 5.3 4.3 5.9 0.257
SDS 3.7 4.7 2.4 4.3 0.089
Positive ECG 6 (22) 79 (12) 0.124
TID 2 (7) 52 (8) 1.000
Stress LVEF 50% 5 (19) 171 (25) 0.505
Stress LVEF 60 11 59 16 0.928
Rest LVEF 56 10 53 14 0.630
LVEF reserve 4.6 7.2 5.6 8.6 0.589
82Rb PET absolute flow quantification
parameters
Rest MBF 1.04 0.42 1.03 0.38 0.873
Stress MBF 2.28 0.84 2.24 0.93 0.746
MFR 2.46 1.03 2.31 0.91 0.363
MFD 1.24 0.84 1.21 0.79 0.632
Values are mean  SD or n (%).
CAD  coronary artery disease; CCS  Canadian Cardiovascular Society; ECG  electrocardio-
ram; LVEF  left ventricular ejection fraction; LVEF reserve  stress  rest LVEF; MBF 
yocardial blood flow; MFD  myocardial flow difference; MFR  myocardial flow reserve; MI 
yocardial infarction; NYHA New York Heart Association; PET positron emission tomography;
82VD peripheral vascular disease; Rb rubidium-82; SDS summed difference score; SSS
summed stress score; TID  transient ischemic dilation.
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August 9, 2011:740–8 Myocardial Flow Reserve by PET and Outcomes in Ischemia13 (13 of 71; 18%) because of congestive heart failure; 15
patients (15 of 71; 21%) due to acute coronary syndrome,
and 1 patient (1 of 71; 1.4%) due to other cardiac causes
(syncope and chest pain and subsequently acute coronary
syndrome).
The results of univariate analysis of baseline demo-
graphics, standard PET imaging features, and 82Rb MBF
uantification parameters for hard cardiac events are
ummarized in Table 2 and those for MACE are sum-
arized in Table 3.
Patients were divided into 4 subgroups according to the
SS and MFR (Fig. 1). The distribution of patients across
he 4 subgroups and the frequency of hard cardiac events
nd MACE in each of these are provided in Table 4.
For those with a normal SSS and impaired MFR com-
ared with those with a preserved MFR, there was higher
ncidence of hard events (2% vs. 1.3%, p  0.029) and a
igher incidence of MACE (9% vs. 3.8%, p  0.003).
mong patients with an abnormal SSS, those with MFR
2 compared with those with a preserved MFR had a
igher incidence of hard events (11.4% vs. 1.1%, p  0.05)
Comparison of Patients Withand With ut Hard Cardiac EventsTable 2 Comparison of Patients Withand Without Hard Cardiac Events
Variable
No MI/Cardiac Death
(n  650)
MI/Cardiac Death
(n  27) p Value
Age, yrs 64 12 64 12 0.924
Male 396 (61) 20 (74) 0.226
Hypertension 441 (68) 20 (74) 0.674
Diabetes 181 (28) 14 (52) 0.015
Smoking 408 (63) 23 (85) 0.023
Family history of CAD 321(49) 15 (56) 0.561
Hyperlipidemia 447 (69) 20 (74) 0.674
PVD 115 (18) 11 (41) 0.009
Known CAD 366 (56) 24 (89) 0.001
Previous MI 245 (38) 23 (85) 0.001
Previous revascularization 284 (44) 19 (70) 0.009
CCS angina class II 258 (40) 16 (59) 0.047
NYHA functional class II 197 (30) 11 (41) 0.287
82Rb PET standard imaging
parameters
SSS 4.1 5.7 10.1 7.8 0.001
SDS 2.3 4.1 5.6 5.7 0.001
Positive ECG 75 (12) 4 (15) 0.543
TID 48 (7) 4 (15) 0.145
Stress LVEF 50% 155 (24) 16 (59) 0.001
Stress LVEF 60 15 43 17 0.001
Rest LVEF 54 14 42 16 0.001
LVEF reserve 5.8 8.5 0.62 93 0.011
82Rb PET absolute flow
quantification parameters
Rest MBF 1.04 0.38 0.89 0.38 0.018
Stress MBF 2.28 0.91 1.30 0.85 0.001
MFR 2.33 0.90 1.46 0.70 0.001
MFD 1.25 0.78 0.41 0.66 0.001
Values are mean  SD or n (%).
Abbreviations as in Table 1.nd a higher incidence of MACE (24% vs. 9%, p  0.001).All cardiac deaths occurred in patients with an abnormal
FR (1 [1%] in group II; 11 [6.5%] in group IV). All
atients who experienced cardiac death had a severely
mpaired MFR (MFR 1.5).
Figure 2 shows adjusted event-free survival curves for
ard events and MACE in the different subgroups.
ultivariable Cox models. The 82Rb MFR was an inde-
endent predictor of cardiac hard events (hazard ratio [HR]:
.3, 95% confidence interval [CI]: 1.1 to 9.5); p  0.029).
he incremental prognostic value of the MFR over the SSS
as also shown by comparing the adjusted SSS models
ithout and with the MFR (p  0.0197). When only the
SS (HR: 3.1, 95% CI: 1.2 to 8.1; p  0.018) and previous
I (HR: 6.0, 95% CI: 2.0 to 18.1; p  0.002) were
onsidered in the model, both were independent predictors.
hen stress LVEF was added (HR: 0.82, 95% CI: 0.72 to
.93; p  0.002), it was significant. At this point, only MI
nd stress LVEF were significant in the adjusted model.
he SSS and stress LVEF were collinear (  0.6), which
resulted in the SSS not being significant. Adding the MFR
to the model resulted in the best fit (likelihood ratio test,
p  0.0197) and confirmed the added independent prog-
nostic value of this parameter (Table 5). With 3 individuals
Comparison of Patients With and Without MACETable 3 Comparison of Patients With and Without MACE
Variable
No MACE
(n  606)
MACE
(n  71) p Value
Age, yrs 64 12 63 11 0.740
Male 372 (61) 44 (62) 1.000
Hypertension 413 (68) 48 (68) 1.000
Diabetes 164 (27) 31 (44) 0.005
Smoking 379 (63) 52 (73) 0.090
Family history of CAD 303 (50) 33 (46) 0.617
Hyperlipidemia 418 (69) 49 (69) 1.000
PVD 104 (17%) 22 (31%) 0.009
Known CAD 338 (56) 52 (73) 0.005
Previous MI 222 (37) 46 (65) 0.001
Previous revascularization 265 (44) 38 (54) 0.131
CCS angina class II 235 (39) 39 (55) 0.010
NYHA functional class II 180 (30) 28 (39) 0.103
82Rb PET standard imaging
parameters
SSS 3.84 5.63 8.17 6.98 0.001
SDS 2.16 4.03 4.93 5.05 0.001
Positive ECG 68 (11) 11 (15) 0.326
TID 41 (7) 11 (15) 0.016
Stress LVEF 50% 137 (23) 34 (48) 0.001
Stress LVEF 60 15 48 18 0.001
Rest LVEF 54 14 46 17 0.001
LVEF reserve 6.0 8.5 2.1 9.1 0.001
82Rb PET absolute flow
quantification parameters
Rest MBF 1.04 0.38 0.92 0.38 0.003
Stress MBF 2.31 0.90 1.61 0.94 0.001
MFR 2.36 0.91 1.74 0.75 0.001
MFD 1.27 0.77 0.68 0.74 0.001Values are mean  SD or n (%).
MACE  major adverse cardiac event(s); other abbreviations as in Table 1
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Myocardial Flow Reserve by PET and Outcomes in Ischemia August 9, 2011:740–8classified up and 0 classified down with the MFR in the
model, the net reclassification improvement was estimated
at 0.11 and showed a trend toward significance (p 0.092).
he integrated discrimination improvement estimated at
.009 was significant (p  0.001).
The 82Rb MFR was also an independent predictor of
ACE (HR: 2.4, 95% CI: 1.4 to 4.4; p  0.003). In the
odel without the MFR, the SSS 4, diabetes, Canadian
ardiovascular Society (CCS) angina class II and stress
VEF were independent predictors of MACE. The effect
f adding the MFR resulted in better fitting of the model
p  0.002), after controlling for the significant covariate
SS (HR: 1.9, 95% CI: 1.03 to 3.6; p  0.041), diabetes,
CS angina class, and stress LVEF (Table 6). This incre-
ental value is also supported by the significant net reclas-
ification improvement (0.112, p  0.048) and integrated
discrimination improvement (0.014, p  0.001). Among
the flow parameters, the MFR provided the most significant
independent prognostic value for both hard events and
MACE.
Figure 1 Box Plots Demonstrating the Distribution of MFR Acr
  mean;   minimum value 1.5 (interquartile range) below the 25th percen
quartile range 75th to 25th percentiles; crossbars  25th, 75th, and 50th (media
SSS  summed stress score.
Incidence of Hard Cardiac Events and MACE Across Group CategorTable 4 Incidence of Hard Cardiac Events and MACE Across G
Outcomes (n  678)
SSS <4 (n  414)
Group I: MFR
>2 (n  314)
Group II: MFR
<2 (n  100)
MI/cardiac death (n  27) 4 (1.3) 2 (2)
MACE (n  71) 12 (3.8) 9 (9)Values are n (%). *p values are based on Cox model contrasts.
Abbreviations as in Tables 1 and 3.MACE in subgroup categories of SSS and MFR. The
percentage of MACE was analyzed at different levels of the
SSS: SSS 4, SSS 4 to 7, SSS 8. With the aim of
understanding the impact of progressive reductions in MFR
on outcomes; MACE were evaluated at different degrees of
MFR impairment (MFR 2, MFR 1.9 to 1.5, MFR 1.5)
in different the SSS categories. At any level of the SSS, the
incidence of MACE was highest in patients with the lowest
MFR (1.5) (Fig. 3).
Regional MFR. We conducted exploratory analyses in pa-
tients with a normal global MFR (2). We observed that
patients with abnormal regional MFR in a single-vessel terri-
tory compared with those with normal MFR in all vascular
territories had increased MACE (9 of 94; 9.6% vs. 11 of 300;
3.7%; unadjusted p  0.015, adjusted p  0.024) and a trend
or hard events (3 of 94; 3.2% vs. 2 of 300; 0.7%; unadjusted
 0.083, adjusted p  0.135). Among those with normal
global MFR and abnormal regional MFR, there was no
significant difference in events for those with and without
an abnormal SSS. Eight patients with abnormal MFR in
ubgroups
 maximum value 1.5 (interquartile range) above the 75th percentile; inter-
centiles; circles  outliers. HR  hazard ratio; MFR  myocardial flow reserve;
Categories
SSS >4 (n  263)
Value*
Group III: MFR
>2 (n  88)
Group IV: MFR
<2 (n  175) p Value*
0.029 1 (1.1) 20 (11.4) 0.05
0.003 8 (9) 42 (24) 0.001oss S
tile; T
n) periesroup
p
b
r
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those with an impaired global MFR, it was uncommonly
(17 of 275; 6.2%) attributable to a significant reduction in
MFR in 1 vascular territory. The number of events was too
small to allow conclusive comparisons.
Discussion
This study is one of the first to demonstrate the added and
Figure 2 Adjusted Cardiac Hard Event-Free Survival and Event-
(A) Adjusted cardiac hard event–free survival. Arrows highlight the statistically sig
major adverse cardiac event–free survival. Arrows highlight the statistically significindependent prognostic value of MFR using 82Rb PETeyond the relative MPI in a large cohort of patients
eferred for assessment of ischemia. Patients with impaired
82Rb MFR had a higher incidence of hard cardiac events
and MACE at approximately 1-year follow-up. In the
multivariable model analysis, 82Rb MFR was an indepen-
dent predictor of hard events and MACE over the SSS.
Comparison with previous PET studies. At least 4 pre-
vious studies assessed the prognostic value of standard
Survival Curves
t differences in outcomes among subgroups. (B) Adjusted
fferences in outcomes among subgroups. Abbreviations as in Figure 1.Free
nifican
ant direlative MPI using PET with 82Rb (3–6). These studies are
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Myocardial Flow Reserve by PET and Outcomes in Ischemia August 9, 2011:740–8difficult to compare because there are important variations
in: 1) population; 2) PET technology and protocol; and
3) endpoints. Studies included 367 to 1,442 patients,
with 31% to 70% of patients with known CAD and
evaluated hard events, MACE, or all-cause mortality
(3– 6). The studies each concluded that abnormal relative
perfusion is associated with a worse prognosis. Two more
recent studies showed that there was added prognostic
value using the LVEF (5,6). However, none of these
studies measured the absolute myocardial flow. Our study
is unique because it is the first to assess the prognostic
value of MFR for hard events with 82Rb PET in a large
population.
In the setting of ischemic heart disease, Tio et al. (15)
showed that MFR measured with 13NH3 PET predicts
dverse outcomes in patients with severe CAD and left
entricular dysfunction who were not candidates for revas-
ularization. This is a different population from that in the
urrent study, which evaluated patients referred for assess-
ent of ischemia including patients with and without
nown CAD. The current study population was more
omparable to that of Herzog et al. (14) who demonstrated
he incremental utility of the MFR with 13NH3 PET over
Multivariable Cox Models of Hard Cardiac Events for Prognostic VaTable 5 Multivariable Cox Models of Hard Cardiac Events for P
Parameter Chi-Square test
SSS*  MI history
SSS 5.6
MI 10.0
SSS*  MI history  stress LVEF†
SSS 0.76
MI 8.1
Stress LVEF 9.8
SSS*  MI history  stress LVEF†  MFR§
SSS 0.07
MI 8.4
Stress LVEF 5.8
MFR 4.8
*4 vs. 4. †Per 5-U increase. ‡p  0.002 (likelihood ratio test). §2 vs. 2. p  0.0197 (like
CI  confidence interval; other abbreviations as in Table 1.
Multivariable Cox Models of MACE for Prognostic Value of MFR CoTable 6 Multivariable Cox Models of MACE for Prognostic Valu
Parameter Chi-Square test
SSS*  baseline  stress LVEF†
SSS 8.6
CCS angina class 9.5
Stress LVEF 15.9
DM 4.1
SSS*  baseline  stress LVEF†  MFR§
SSS 4.2
CCS angina class 9.7
Stress LVEF 9.3
DM 3.2
MFR 8.9*4 vs. 4. †Per 5-U increase. ‡p  0.002 (likelihood ratio test). §2 vs. 2.
Baseline  baseline demographic parameters; DM  diabetes mellitus; other abbreviations as in Tabltandard relative MPI for predicting outcomes. Compared
ith Herzog et al. (14) study, the current study has a larger
ample size (N  677 vs. N  229), similar percentage of
ale patients (61% vs. 69%), slightly fewer patients with
nown CAD (58% vs. 66%), a similar percentage of patients
ith MFR 2 (41% vs. 44.5%), but fewer patients had
bnormal MPI (39% vs. 55%) and shorter follow-up. In line
ith Herzog et al. (14), our results show that: 1) in patients
ith normal and abnormal relative 82Rb PET perfusion,
ubgroups with reduced MFR had a worse prognosis than
heir normal 82Rb MFR counterparts; and 2) MFR on 82Rb
ET was an independent predictor of hard events (HR: 3.3,
5% CI: 1.1 to 9.5; p  0.029) and MACE (HR: 2.4, 95%
I: 1.4 to 4.4; p  0.003) after adjusting for relative MPI
and other confounding variables. 82Rb MFR improves risk
stratification.
The present study also evaluated the effect of reducing
MFR in different SSS subgroups. At any level of SSS, the
percentage of MACE was highest among patients with the
lowest MFR (1.5) and statistically significant among
those with an abnormal SSS (4). Among patients with
cardiac death (n  12), all had significantly reduced MFR
(1.5). Also, we assessed and observed that stress LVEF
f MFR Compared With SSSstic Value of MFR Compared With SSS
e Hazard Ratio 95% CI Deviance Statistic
318.747
8 3.1 1.2–8.1
2 6.0 2.0–18.1
309.222‡
2 1.6 0.56–4.5
5 5.0 1.7–15.4
2 0.82 0.72–0.93
303.662
6 1.2 0.39–3.4
4 5.2 1.7–15.8
6 0.85 0.75–0.97
9 3.3 1.1–9.5
ratio test).
red With SSSMFR Compared With SSS
e Hazard Ratio 95% CI Deviance Statistic
830.718
3 2.4 1.3–4.4
2 2.1 1.3–3.4
1 0.85 0.79–0.92
3 1.6 1.02–2.60
821.24‡
1 1.9 1.03–3.60
2 2.1 1.3–3.4
2 0.88 0.81–0.96
4 1.5 0.96–2.50
3 2.4 1.4–4.4lue orogno
p Valu
0.01
0.00
0.38
0.00
0.00
0.79
0.00
0.01
0.02mpae of
p Valu
0.00
0.00
0.00
0.04
0.04
0.00
0.00
0.07
0.00es 1 and 5.
w
c
w
c
e
I
h
p
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t
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comes, extending findings of previous studies (5). Finally,
we used 82Rb, which, as a generator product, can be more
idely distributed; thus, it has greater potential for wide
linical use compared with 13NH3 and H2
15O.
Clinical implications. Routine integration of 82Rb MFR
ith relative MPI could represent a valuable tool for the
linician to better stratify a patient’s risk of adverse cardiac
vents. Abnormal 82Rb MFR means worse outcomes in any
category of relative MPI, and this could affect management
decisions for these patients. Even in those with mildly
abnormal relative MPI who may be considered for medical
therapy, impaired 82Rb MFR had worse outcome (Fig. 3).
dentification of impaired 82Rb MFR in this group could
ave important impact on decisions for invasive angiogra-
hy and revascularization. In patients with normal standard
elative perfusion, reduced 82Rb MFR would also indicate a
worse prognosis, and this could also affect management and
dictate the need for more aggressive medical therapy and
closer follow-up of the patient. On the other hand, because
patients with moderate to severe SSS on relative MPI may
already be more likely to undergo invasive angiography and
revascularization, the added value of impaired 82Rb MFR
ay be less in this group but may still affect decisions for
hose who are at high risk of intervention. Because all
ardiac deaths occurred in patients with severely reduced
82Rb MFR (1.5), it may also be that this signifies a
particularly high-risk group. Further studies would be re-
quired to understand the impact of MFR on directing
decision making to affect outcome.
Our rubidium generator and elution system (20) are
different from those used in other laboratories, but the
rubidium 1-tissue-compartment model used for flow quan-
Figure 3 MACE Within Subgroups of SSS for Different Levels o
At any level of SSS, the prevalence of MACE is higher in patients with the lowest M
patients with overt ischemia. *p  0.028 for SSS 4 to 7 and MFR 1.5 versus
adverse cardiac events; other abbreviations as in Figure 1.tification (24) should yield similar results with data fromother systems. Our low-dose rubidium protocol was devel-
oped expressly to limit the peak dead-time losses with
3-dimensional PET while maintaining high-quality images
(20). The rubidium activity can be infused over a longer
interval to reduce the peak dead-time losses, improving the
accuracy and precision of the resulting flow values. Three-
dimensional mode PET imaging has been the approach
used in our validation studies and assessment of intra- and
interoperator variability (16). Three-dimensional imaging is
now standard on all new PET scanners.
Study limitations. This study is observational and single
centered; thus, there may be selection bias in patients
referred for PET MPI. There were only 27 hard events,
and overfitting the model for hard events may be a
concern. The results need to be confirmed in a larger
cohort with more hard events. PET MBF parameters
were not available in the clinical report for the referring
physicians during the course of this study period; man-
agement direction and decision making were not influ-
enced by PET MBF quantification.
82Rb has lower extraction fraction, which may affect the
precision at hyperemic flow measurements, a higher posi-
tron range, which can reduce image resolution, and a
relatively short half-life for imaging perfusion and function
in patients with reduced left ventricular function. However,
data support that flow quantification with 82Rb is feasible,
accurate, and reproducible (27–29) and has been validated
against microspheres (30). As such, 82Rb PET flow quan-
tification has promise for risk stratification.
We focused primarily on global MFR that reflects diffuse
(12,13) and potentially greater disease burden (7). Previous
data in nonischemic and ischemic heart disease do suggest a
potential prognostic value of global MFR measurements.
1.5) and statistically significant different compared with MFR 2 among
2. **p  0.002 for SSS 8 and MFR 1.5 versus MFR 2. MACE  majorf MFR
FR (
MFR We did explore regional MFR in patients with normal
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MFR had increased MACE, suggesting that there may be
added value for regional MFR. Among those with impaired
global MFR, it was uncommonly (6.2%) attributable to
significant reduction in MFR in 1 vascular territory, thus
making conclusive findings on regional MFR difficult.
Larger studies will be required.
There is some interest in stress MBF as an independent
parameter and indeed stress MBF is useful, but in the
current study, MFR was the more significant predictor of
outcome.
Conclusions
In a large cohort of patients referred for PET MPI to assess
myocardial ischemia, assessment of MFR with 82Rb yields
ndependent and added prognostic information beyond
elative MPI. Clinical integration of MFR with relative
ET MPI will enhance risk stratification in this patient
opulation.
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